Study:
A Phase III Randomized Trial of Intravenous Paclitaxel and Cisplatin Versus Intravenous Paclitaxel, Intraperitoneal Cisplatin and Intraperitoneal Paclitaxel in Patients With Optimal Stage III Epithelial Ovarian Carcinoma or Primary Peritoneal Carcinoma
Rationale:
Drugs used in chemotherapy use different ways to stop tumor cells from dividing
so they stop growing or die. Combining more than one drug and giving drugs in different ways
may kill more tumor cells. It is not yet known whether intravenous two-drug combination
chemotherapy is more effective than intravenous and intraperitoneal infusions of three-drug
combination chemotherapy for treating primary peritoneal or stage III epithelial ovarian
cancer.
Purpose:
Randomized phase III trial to compare the effectiveness of intravenous two-drug
combination chemotherapy with intravenous and intraperitoneal three-drug combination
chemotherapy in treating patients who have primary peritoneal or stage III epithelial
ovarian cancer.
Study Status: Completed
Recruiting:
n/a
| Condition |
Intervention |
Phase |
Ovarian Cancer
Primary Peritoneal Cavity Cancer |
Drug: cisplatin
Drug: paclitaxel
Procedure: quality-of-life assessment |
Phase 3 |
Verified by
Gynecologic Oncology Group
August, 2012
Sponsored by: Gynecologic Oncology Group
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov identifier: NCT00003322
Study Type: Interventional
Study Design: Allocation: Randomized, Primary Purpose: Treatment
Cleveland Clinic Cancer Center
Cleveland, Ohio 44195
United States
Deborah K. Armstrong, MD., Study Chair